Research Article

Development and Characterization of an Ex Vivo Arterial Long-Term Proliferation Model for Restenosis Research

Daniela Haase 1, Sylvia Otto 1, Bernd F. M. Romeike 2, Hans R. Figulla 1 and Tudor C. Poerner 1

1 Clinic of Internal Medicine I, Jena University Hospital, Friedrich Schiller University of Jena, Germany; 2 Institute of Pathology, Jena University Hospital, Friedrich Schiller University of Jena, Germany

Summary

One of the main limitations of percutaneous coronary interventions is restenosis, occurring in small-diameter arteries. Many efforts are underway to find improved intracoronary devices to prevent in-stent restenosis. The aim of this study was to produce a new in vitro test platform for restenosis research, suitable for long-term cell proliferation and migration studies in stented vessels. Fresh segments of porcine coronary arteries were obtained for decellularization and were then reseeded with human coronary artery endothelial (HCAEC) and human coronary artery smooth muscle cells (HCASMC). Subsequently, bare metal stents (BMS) or drug eluting stents (DES) were implanted and the segments were reseeded with HCAEC and HCASMC for up to three months. The stented segments were examined at time zero and after 2, 4, 6, 8 and 12 weeks by histochemical and immunohistochemical characterization and the reseeded areas before and after stent implantation were measured. Cells formed multiple layers after three months and detection of both CD31 and α-smooth muscle actin by specific antibodies showed that HCAEC and HCASMC are adherent and growing in several layers. Furthermore, we could show a significantly smaller proliferation area in DES (70% ± 3.5%) compared to BMS (17% ± 2.3%). These data are similar to animal and human studies. Therefore, this vessel model might be suitable as an initial benchmark for testing new anti-proliferative endovascular therapies and could consequently help to reduce animal experiments in this research area.

Keywords: restenosis, coronary arteries, decellularization, reseeding

1 Introduction

Cardiovascular disease is the leading cause of mortality in Europe and the United States (Lloyd-Jones et al., 2009). Endovascular stents have lowered acute complication rates and improved long-term follow-up of coronary interventions, which are mainly limited by the occurrence of restenosis (Gruberg et al., 2000).

Restenosis is basically due to neointimal hyperplasia triggered by lesions of the vessel wall during stent implantation (Rosanio et al., 1999). Endothelial cells of the intima as well as inflammatory cells from subintimal layers release cytokines that induce vascular smooth muscle cells (SMC) to migrate from the media to the intima and proliferate (Salabei and Hill, 2014). Therefore, drug eluting stents (DES) have been developed, which slowly release anti-proliferative substances to the surrounding tissue (Katz et al., 2015). Despite a reduction of the restenosis rate in DES compared with bare metal stents (BMS), late in-stent restenosis (ISR) has not been abolished (Stefanini and Holmes, 2013; Stettler et al., 2007; Akin et al., 2011). The mechanisms leading to DES restenosis are the development of neoatherosclerosis and also local inflammatory processes triggered by the anti-proliferative substance, the polymer, or the stent struts themselves (Byrne et al., 2009; Pfisterer et al., 2006). Currently available DES elute mainly mTor inhibitors (sirolimus, everolimus, biolimus or zotarolimus) and less paclitaxel, with or without a polymeric carrier (Sanchez et al., 2015; Sheth and Giugliano, 2014). The anti-proliferative effects are obtained at the cost of a significantly prolonged period of endothelialization of the stent struts and thus a dual anti platelet therapy (DAPT) of at least 6 months is indicated for DES

Received March 5, 2015;
Accepted September 10, 2015;
Epub September 24, 2015;
http://dx.doi.org/10.14573/altex.1503051

This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is appropriately cited.
whereas a 4-week DAPT is regarded sufficient after BMS implantation for prevention of stent thrombosis (Kolh et al., 2014). Therefore, many efforts are underway to find the ideal trade-off between selective inhibition of the proliferation and migration of smooth muscle cells on one side and delayed stent coverage on the other (Nakazawa et al., 2008, 2011).

The goal of the present study was to produce an in vitro vessel model for DES testing, which should spare animal experiments by eliminating devices that have either insufficient anti-proliferative properties or induce cytotoxic reactions in endothelial cells.

2 Materials and methods

2.1 Specimen

All animal samples were obtained from waste of the local slaughterhouse. Freshly excised segments of porcine coronary arteries (4 mm diameter, 6-10 cm length) were separated from surrounding tissue prior to decellularization. Each vessel was divided into one control sample and one sample undergoing the decellularization procedure. For mechanical testing, the segments had a length of at least 8 cm.

2.2 Decellularization

For decellularization, several protocols were tested. The combinations of chemical, enzymatic and physical treatment are shown in Table 1. For all protocols, each incubation step was followed by a 24 h washing step with PBSA (phosphate buffered saline including 1% penicillin/streptavidin and 1% partricin A, PAA, Linz, Austria).

All treated and untreated samples were subsequently stored in sterile PBSA at 4°C.

2.3 Verification of decellularization

Histological staining and microscopy

Histological examination of samples underlying decellularization and of control samples was performed using hematoxylin-eosin (HE), Elastica-van-Gieson (EvG) and 4′,6-diamidin-2-phenylindol (DAPI) staining.

For HE staining, paraffin-embedded tissue was cut into 5 μm sections using a rotary microtome (RM 2165, Leica, Wetzlar, Germany), transferred to slides and dewaxed, followed by 5 min incubation in Mayer’s hematoxylin (Roth, Karlsruhe, Germany), 5 min wash in running tap water and 3 min incubation in eosin solution (0.5%, Roth). EvG staining was done by 1 h incubation in Weigert’s resorcin-fuchsin solution (Roth), iron hematoxylin (Roth) for 3 min and van-Gieson-solution (Hollborn, Leipzig, Germany) for 10 min. For DAPI staining, paraffin-embedded samples were mounted with Vectashield Mounting Medium for fluorescence (Vector Laboratories, Inc., CA, USA). After staining, slides were imaged by light and fluorescence microscopy (AxioVision, Zeiss, Jena, Germany) using 100 x, 200 x and 400 x objectives.

DNA analysis

Genomic DNA of decellularized and non-decellularized arterial tissue was isolated using the DNeasy tissue kit (Qiagen, Hildesheim, Germany) according to the manufacturer’s instructions. The presence or absence of genomic DNA was proven by spectrophotometric measurement at 260/280 nm (NanoDrop Technologies Inc., Wilmington, USA) and agarose gel electrophoresis.

Mechanical characterization

The mechanical behavior of the decellularized versus non-decellularized tissue was assessed using a stretch test and an opening angle test.

For the stretch test, arterial segments of equal length and thickness were clamped in a TIRAtest 2420 machine (TIRA GmbH, Schalkau, Germany) and expanded under uniaxial loading at a rate of 10 mm/min as previously described (Bolland et al., 2007). Pull-out forces at elongations of 20 and 30 mm were recorded in Newton (N) and calculations were performed using the TIRAsoft software (TIRA GmbH, Schalkau, Germany).

Fresh arterial and decellularized arterial segments were cut into ring segments (n = 5 per sample) to prepare the opening angle test as previously described (Williams et al., 2009). Rings were equilibrated in isotonic saline solution for 30 min, radially cut and again equilibrated for 30 min. Images were taken using a digital camera and the opening angle was measured using ImageJ 1.43 software (National Institutes of Health, USA).

These experiments were repeated three times.

2.4 Cell culture and scaffold seeding

The primary cell lines HCASMC (human coronary artery smooth muscle cells) and HCAEC (human coronary artery
endothelial cells) were purchased from Lonza (Basel, Switzerland). Cells were maintained in Smooth Muscle Cell Growth Medium 2 and Endothelial Cell Growth Medium, respectively (PromoCell, Heidelberg, Germany) at 37°C in 5% CO2. For reseeding of scaffolds, 1x10^4 cells per cm² were added three times a week. Cells were pipetted directly into the lumen of the vessel; allowed to settle for 15 min and then the vessel was axially rotated by 90 degrees. This procedure was repeated three times until the entire lumen was seeded, and then medium was added back. Parallel samples were run for HCASMC and HCAEC, respectively, and for HCASMC and HCAEC in coculture.

2.5 Stent implantation
To investigate the effects of coronary stents on the reseeded vessels, we implanted different DES (4 paclitaxel [TAXUS® Express²™, Boston Scientific], 4 everolimus [XIENCE V®, Abbott Vascular] and 2 zotarolimus [Resolute® Integrity, Medtronic] eluting stents) and 2 different bare metal stents (DRIVER® Sprint, Medtronic and MULTI-LINK ZETA®, Abbott Vascular). The stented vessels were seeded with HCASMC and HCAEC and samples were collected at time zero and after 2, 4, 6, 8 and 12 weeks.

2.6 Cell growth assays
To test for cytotoxic components remaining after the decellularization procedure, cell seeding experiments were performed under standard culture conditions. A 1 cm² sheet of decellularized specimen was put into the well of a 24-well culture plate. The assay was performed as previously described (Kimuli et al., 2004). Briefly, smooth muscle cells and endothelial cells (passage 4, at a density of 1 x 10^4 cells/10 µl) were added to the luminal surface of the specimen. Cells were cultured in appropriate growth medium. After an incubation period of 1 or 14 days, specimens were washed three times with PBS and incubated with 10 µM calcein-AM (Life Technologies Inc., Darmstadt, Germany) for 30 min at room temperature. Images were acquired using an inverse microscope (Axiovert, Zeiss, Jena, Germany).

Cell viability assays were performed as previously reported (Haase et al., 2010). Briefly, cells were seeded in the lumen of stented and non-stented decellularized scaffolds. After 0 h and after 2, 4, 6, 8 and 12 weeks, a sample of 1 cm length was cropped, radially cut and 10 µl of 5 mg/ml (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich, Taufkirchen, Germany) was added for 4 h. Then 100 µl of solution buffer (10% SDS, 0.01 M HCl) was added for overnight incubation. Samples were transferred to a 96-well plate and absorbance at 570 nm was measured. These experiments were carried out in replicates of five.

2.7 PCR
Total RNA from arterial vessels reseeded for 12 weeks was extracted with the RNeasy Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s instructions. RNA was adjusted to 1 µg/10 µl for reverse transcription (Reverse Transcription System, Promega, WI, USA). CD31, alpha-smooth muscle actin (α-SMA) and beta-actin expression levels were analyzed by PCR on the UNO II cycler (Biometra, Göttingen, Germany) using the DyNAzyme DNA Polymerase Kit (Finnzymes, MA, USA). The sequences of the primers were as follows: CD31(sense) 5'-ATGGGGTCAGTTCCA TTTC-3'; CD31(antisense) 5'-CAGGTGTGGCCAATGCT TCT-3'; α-SMA(sense) 5'-CCATCAAATGCCTGTGGTA -3'; α-SMA(antisense) 5'-GATGACCCAGTATGTT TGA-3'; beta-actin(sense) 5'-ACCACCCCAAGCATGTACG-3'; beta-actin(antisense) 5'-ATGTACGCACGA-TTCCC-3'. Cycling conditions were as follows: 10 min initializing denaturation, followed by 40 cycles of 95°C for 20 s, 55°C for 20 s (58°C for CD31 and α-SMA) and 72°C for 30 s. PCR products were analyzed by agarose gel electrophoresis.

2.8 Free float staining and embedding of stented scaffolds
The stented scaffolds were stained in the appropriate solutions in 15 ml tubes. Steps for HE and EvG staining were approached as described above. After staining, specimens were dehydrated, dried and embedded in a synthetic resin (Spezifix 20, Struers, Ballerup, Denmark). Sawing was performed using a low speed precision saw (ISOMET, Buehler, Illinois, USA) and the resulting sections were ground to 300 µm thickness using the grinder PHOENIX 400 (Buehler, Illinois, USA) and abrasive paper.

2.9 Immunostaining
Immunostainings of CD31 and alpha-smooth muscle actin in fresh tissue sections were performed using polyclonal CD31 (Dako, Hamburg, Germany) and alpha-smooth muscle actin (Abcam, Cambridge, UK) antibodies at a concentration of 1:500 for 1 h at room temperature, followed by Cy-3 and Cy-2-conjugated secondary antibody (Beckman, CA, USA) incubation for an additional 1 h in the dark. Nuclei were stained using mounting medium containing DAPI (Vector Laboratories, Inc., CA, USA). Images were taken with a laser scanning microscope (LSM510, Zeiss, Jena, Germany).

2.10 Data analysis and statistics
For analysis of cell growth inhibition after stent implantation, images were taken before and after stent implantation using a light microscope (Axioplan 2, Zeiss, Jena, Germany). The reseeded area was defined as the area between the outside of the vessel and the vessel lumen and was measured using ImageJ software (version 1.4.3, National Institutes of Health, USA). After 12 weeks of reseeding (day of stent implantation [t0]), the measured area of a vessel was defined as 100% and all following measurements of the same vessel were related to this.

Statistical analysis was performed using SPSS for Windows (version 13.0). Continuous variables are given as mean values ± SD. Stretch test, opening angle test and cell growth inhibition were analyzed for statistically significant differences by Student’s two-tailed t-test for unpaired samples. Differences with p ≥ 0.05 are defined as not significant. Significant p-values are indicated with asterisks.
3 Results

3.1 Characterization of decellularized arterial vessels

Compared to native vessels, a complete decellularization was obtained with protocol D (see Tab. 1; Fig. 1A). This was confirmed by the complete absence of DNA fragments. EvG staining and microscopic evaluation demonstrated hardly any differences between control segments and completely decellularized segments regarding the structure of the extracellular matrix (Fig. 1B-D). The stretch test revealed no significant differences between fresh and decellularized vessels in the applied force for an elongation of 20 mm (8.87 ±0.57 N and 10.03 ±1.83 N; p = 0.414) and 30 mm (18.47 ±2.26 N and 21.31 ±1.56 N; p = 0.147) (Fig. 2A).

Also, native vessels had no significantly greater opening angles compared with the decellularized vessels (66.8 ±7.4° and 49.1 ±9.8°; p = 0.0518), indicating no significant reduction in the tensile stresses after decellularization (Fig. 2B).

A monolayer of HCASMC and HCAEC could be detected on the luminal surface of the decellularized specimen 14 days after cell seeding (Fig. 3A). Control wells without the arterial sam-

![Fig. 1: Treatment with 4% sodium deoxycholate, 0.25% Triton X-100 and subsequent incubation with DNase I and RNase A results in complete decellularization](image-url)

A: Paraffin-embedded sections of porcine artery before and after decellularization. HE staining reveals blue-stained cell nuclei in the control segment (a) and complete decellularization in treated segments (b).

B: DAPI staining before (a, c) and after (b, d) decellularization treatment. The luminous blue color indicates the nuclei. Images (c) and (d) are higher magnifications of (a) and (b), respectively.

C: EvG staining shows the structure of the elastic (black-violet) and collagen (pink-red) fibers without differences between control (a) and completely (b) decellularized segments.

D: Gel electrophoresis confirms the complete absence of DNA fragments using protocol D. Lanes 1, 2 and 4 show residual genomic DNA, whereas lane 3 is completely free of DNA. Legend: (M) standard DNA ladder, (1, 2) partially decellularized artery, (3) completely decellularized artery, according to protocol D, (4) control arterial segment.

Scale bars 100 µm; in 1B scale bars 100 µm (a, b) and 50 µm (c, d).
Fig. 2: Decellularization does not affect mechanical properties of the arterial tissue
A: (a) Example of an arterial segment subjected to a stretch test using the TIRA-test 2420 machine. (b) Decellularized vs. non decellularized arterial segments underwent mechanical stretching. The graph shows no significant differences between the groups. Segments were expanded under uniaxial loading at a rate of 10 mm/min. Pull-out force (in Newton) was measured after an elongation of 20 and 30 mm (mean values ± SD, n = 3; p ≥ 0.05).
B: Representative images for native (a) and decellularized (b) arterial segments for opening angle measurement (α = 64°, β = 48°). (c) Opening angles in native arteries were not significantly greater compared with decellularized ones, indicating no reduction in tensile stresses after decellularization (n = 15; p ≥ 0.05).

Fig. 3: Decellularization conditions do not cause cytotoxicity of the matrix
A: Fluorescence imaging of endothelial (a, b) and smooth muscle cells (c, d) seeded on a decellularized porcine artery and stained with calcein-AM; (a, c) after 1 day of culture, (b, d) after 2 weeks of culture. Scale bars 100 µm.
B: MTT assay shows no significant differences in the cell viability of HCAEC, HCASMC and both cell lines in co-culture.
the cell lines alone and in co-culture as shown by HE staining. RT-PCR of the reseeded vessels showed distinct bands for HCAEC-specific (CD31) and HCASMC-specific (α-smooth muscle actin) primers (Fig. 4B). Detection with CD31 and α-smooth muscle actin specific antibodies showed that both HCAEC and HCASMC are adherent on the decellularized matrix and growing in several layers (Fig. 4C). Thus, optimal cell growth to mimic in-stent proliferation could be achieved by reseeding the decellularized scaffold with both cell lines in co-culture over 12 weeks.

Fig. 4: Reseeding with human coronary artery endothelial (HCAEC) and human coronary artery smooth muscle cells (HCASMC) mimics neointima proliferation
A: HE staining of frozen sections of reseeded (HCAEC and HCASMC in co-culture) arterial segments over a time period of 12 weeks, showing multiple cell layers after three months.
B: PCR analysis of porcine artery, reseeded for 12 weeks. RT-PCR was done for β-actin, α-smooth muscle actin and CD31.
Legend: (1) reseeded artery; (2) before decellularization; (3) after decellularization.
C: Immunofluorescence labelling of reseeded segments with (a) anti human α-smooth muscle actin (green) and (b) anti human CD31 (red) antibodies. Nuclei are stained with DAPI (blue); images were taken with the LSM510, Zeiss.
D: EvG staining of decellularized arterial segments, reseeded with HCAEC and HCASMC with (a) and without (b) implantation of a bare metal stent. MTT assay shows little difference in the cell viability of stented and non-stented segments over the whole time period (c).
Scale bars in C = 50 µm; in D = 100 µm. a.u. = arbitrary units.
Additionally, cell growth was compared between BMS-stented and non-stented vessel segments. There was no significant difference in the formation of the cell layers over the whole time period of 12 weeks (p = 0.138, Fig. 4D).

### 3.3 Inhibition of neointimal proliferation

To evaluate anti-proliferative effects on the engineered vessel segments, we implanted DES and BMS in the samples reseeded with HCAEC and HCASMC and examined them by EvG staining and immunohistochemistry at 2, 4, 6, 8 and 12 weeks compared to baseline. In all stent systems the proliferation area was significantly smaller in the DES compared to BMS (p = 0.0007; Fig. 5A-B). A maximum inhibition of cell growth could be observed in the first six weeks in the DES, whereas only a slight cell decrease could be observed in the BMS over the whole time period (70 ±3.5% and 17 ±2.3%; p = 0.0003). No significant differences between different brands of DES were observed (p =0.074; Tab. 2). Detection with CD31 and α-smooth mus-

---

**Fig. 5: Comparison of BMS and DES in reseeded vessels**

A: EvG staining of reseeded arterial vessels after 12 weeks of stent implantation. Comparison of drug eluting stent (DES) versus bare metal stent (BMS).

B: Significant reduction of the proliferation area in DES-stented vessels. Images of six positions were taken 0 h, 2, 4, 6, 8 and 12 weeks after stent implantation, and the area of cell growth was quantified (mean values ± SD, p-value: * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001).

C: Immunofluorescence labelling of stented segments after 6 weeks with (a, c) anti human α-smooth muscle actin (green) and (b, d) anti human CD31 (red) antibodies. Nuclei are stained with DAPI (blue). (a, b) BMS-stented; (c, d) DES-stented segments. Scale bars 50 µm.
Despite the existence of various decellularization protocols, e.g., for bladder (Bolland et al., 2007) and heart valves (Rieder et al., 2004; Teebken et al., 2009), the efficiency of a method depends mainly on the tissue type. Previously described protocols (Dahl et al., 2003; Williams et al., 2009) did not work properly for arterial vessels.

Of particular interest was the work of Fitzpatrick et al. (2010), who described the decellularization of a porcine descending aorta by using 0.25% sodium-deoxycholate. Since we could not reproduce this condition for a complete decellularization of the arteries, we changed the incubation time and the composition of the chemicals in different steps and found that a high working concentration (4%) of the ionic detergent sodium-deoxycholate in combination with a low amount of the non-ionic detergent Triton X-100 led to complete decellularization. Additionally, all incubation steps were carried out at 37°C.

Actin specific antibodies revealed that both, HCAEC and HCASMC proliferation was reduced in comparative amounts in the DES (Fig. 5C).

Additionally, the cell decrease was determined by measuring the cell viability of the stented vessels by MTT assay at the same time points (see above). Results indicated a significantly lower number of cells in the DES-stented vessels compared to BMS-stented vessels, with the greatest differences between 6 and 8 weeks (p = 0.0002; Fig. 6).

**4 Discussion**

The aim of our study was to engineer an *in vitro* model able to investigate the anti-proliferative effects of new candidate agents.

Initially, in order to design a scaffold for tissue engineering, we developed a decellularization protocol for arterial vessels. In the past, decellularized blood vessels have been studied for their potential use as vascular grafts for small diameter arteries (Antonova et al., 2008; Borschel et al., 2005; Jo et al., 2007; Schaner et al., 2004; Gui and Niklason, 2014). They consist of a natural extracellular matrix, have very low immunogenicity and can be reseeded with various cells of choice and for any period of time (Teebken et al., 2009; Amiel et al., 2006). Though numerous decellularization protocols exist, there was no satisfying procedure for modeling the *in vivo* situation due to significantly altered mechanical characteristics compared to native vessels (Roy et al., 2005; McFetridge et al., 2004).

In this study, we present a new decellularization protocol for small diameter vessels which preserves the composition and mechanical behavior of the extracellular matrix (ECM) without increased stiffness. Despite the existence of various decellularization protocols, e.g., for bladder (Bolland et al., 2007) and heart valves (Rieder et al., 2004; Teebken et al., 2009), the efficiency of a method depends mainly on the tissue type. Previously described protocols (Dahl et al., 2003; Williams et al., 2009) did not work properly for arterial vessels.

Of particular interest was the work of Fitzpatrick et al. (2010), who described the decellularization of a porcine descending aorta by using 0.25% sodium-deoxycholate. Since we could not reproduce this condition for a complete decellularization of the arteries, we changed the incubation time and the composition of the chemicals in different steps and found that a high working concentration (4%) of the ionic detergent sodium-deoxycholate in combination with a low amount of the non-ionic detergent Triton X-100 led to complete decellularization. Additionally, all incubation steps were carried out at 37°C.
According to Gilbert et al. (2006), sodium-deoxycholate is more disruptive than sodium-dodecyl-sulphate (SDS), resulting in a higher damage of the elastic fibers. However, we could not find a degradation of elastic fibers or loss of collagen content as shown by EvG staining. Furthermore, no significant differences in the mechanical behavior of the extracellular matrix could be observed; however, there is a trend towards more stiffness of the decellularized specimen, indicating a minimal alteration of the ECM as a result of the chemical treatment.

Moreover, attention should be paid to the removal of residual chemicals before the further use of such scaffolds. An insufficient removal of the decellularization components may lead to cell damage or in an in vivo setting to an immune response by the host (Rieder et al., 2006). To exclude this potential upset, washing conditions were extended over longer time periods and a cell growth assay was performed to assess the potential cytotoxicity of the decellularized matrix. The resulting viability and adherence of the seeded cells indicate that the decellularized scaffold is not cytotoxic and therefore suitable for further reseeding experiments.

To mimic the formation of a neointima inside the vessels, we reseeded the decellularized matrix with EC and SMC. In standard cell growth assays we observed that SMC grew 3 times faster than EC, so the supposed ratio between SMC and EC on the reseeded vessels is 1:3. This was confirmed by the immunohistochemical data. Because the neointima consists mainly of SMC, this ratio seems representative enough to measure distinct anti-proliferative effects on SMC and EC in this in vitro model.

The process of clinical restenosis proceeds slowly and continuously within the first months after stent implantation, which is the reason why DES release the drug over a long time period (Dangas et al., 2010). In a next step we investigated the effect of BMS and several DES on the reseeded vessels over a time period of 12 weeks. After stent implantation in our model, the expected significant differences in cellular proliferation rates between DES and BMS could be observed (Wallace et al., 2012; Fusaro et al., 2013). Within the DES group, no significant difference in the proliferation area was found, however there is a trend separating “limus” eluting stents (Xience: everolimus, Resolute Integrity: zotarolimus) and paclitaxel eluting stents (PES). These findings are congruent with most clinical studies describing higher ISR rates with PES (Schomig et al., 2007; Mehilli et al., 2010; Otake et al., 2010; Gao et al., 2014). Therefore, even with a very small number of tested stents this model was able to reflect the clinically well-known differences between BMS and DES and also between “limus” eluting stents and PES.

The advantage of the presented model over cell cultures lies in the direct comparison of stented vessels. The clinical effect of a DES is not only dependent on its antirestenotic drug, but also on the stent platform and the polymer carrying the drug. The interaction of these components cannot be simulated by a plain two-dimensional cell culture, which is normally used for simple cell proliferation experiments. By its three-dimensional assembly, this in vitro model is able to model the luminal narrowing as well as the vessel wall structure after stent implantation.

The main limitation factor of the study is the absence of blood cells and therefore the lack of their signals. In vivo, inflammatory cells of the blood, amongst others, mediate the migration to and proliferation of the SMCs in the neointima. To compensate this shortcoming we continued cell seeding for up to 3 months after stent implantation; however, the co-cultivation of a blood cell line is warranted for further studies. The absence of the flow dynamics of the circuit and therefore of shear stress and interaction with endogenous metabolites may impair the validity of the measurements; however, these parameters have to be disregarded for in vitro applications.

Another limitation regards the embedded stent sections. Because the specific synthetic resin is not suitable for immunohistochemistry, stents were removed before histochemical processing and the samples were embedded in paraffin under standard conditions. Though immunohistochemical signals could be obtained, this technique results in a partial loss of the arterial architecture. A further limitation of the study design is the degree of variability concerning the 3-dimensional vessel seeding. Due to the static culturing in cell culture dishes, it was nearly impossible to obtain vessel lumina that are evenly covered by several cell layers. Permanent rotation should overcome this problem, and the use of a bioreactor is expected to yield better results in further studies.

In conclusion, a new arterial matrix reseeded with human endothelial and smooth muscle cells was successfully developed. The present data reflect the anti-proliferative effect of commercially available DES in our model, proving its validity for long-term proliferation and migration studies in stented vessels. Our test platform cannot fully replace the animal studies prior to human clinical trials; however, it has the potential to reduce them in earlier stages of drug testing.

References


Conflict of interest
The authors declare that no conflict of interest exists.

Acknowledgments
The work was supported by grant 031A225 from the German Bundesministerium für Bildung und Forschung (BMBF) and by local institutional funding. We are grateful to Ms. Johanna Gunke and Mr. Carlheinz Holzfuss from the University of Applied Sciences in Jena for kind assistance with the stretch test. We thank Ms. Ines Thiele from the Chair of Materials Science in Jena for technical help with the embedding of stented samples.

Correspondence to
Daniela Haase, PhD
University Hospital Jena
Clinic of Internal Medicine I
Erlanger Allee 101
07743 Jena, Germany
Phone: +49 3641 9324758 / +49 3641 9324113
Fax: +49 3641 9324102
email: daniela.haase@med.uni-jena.de

Erratum

Erratum to Regulatory Acceptance and Use of Serology for Inactivated Veterinary Rabies Vaccines

Marie-Jeanne W. A. Schiffelers 1, Bas J. Blaauboer 2, Wieger E. Bakker 1 and Coenraad F. M. Hendriksen 3

1Utrecht University School of Governance, Utrecht, The Netherlands; 2Utrecht University, Institute for Risk Assessment Sciences (IRAS), Utrecht, The Netherlands; 3Institute for Translational Vaccinology (Intravacc), Bilthoven & Utrecht University, Faculty of Veterinary Medicine, Department Animals in Science and Society, The Netherlands

This manuscript which appeared in ALTEX (2015), 32(3), 211-221, http://dx.doi.org/10.14573/altex.1501261 should have been designated a Research Article and not a Review Article.